As Bluebird’s CAR-T Competition Intensifies, Sickle Cell Therapy Brings Upside

Early Data Suggests Superiority Against Pain Crises

 
• By Andrew McConaghie
  
ASH
The growth of blood cancer pipelines, as well as other hematological disorders, has made ASH a key congress • Source: ASH
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Archive

More from Scrip